Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XCUR Exicure, Inc.

Post-Mkt 03-18 18:48:31 EDT

4.43

-0.11

-2.42%

盘后4.66

+0.23+5.19%

18:24 EDT

High4.66	Low4.34	Vol22.39K
Open4.46	D1 Closing4.54	Amplitude7.05%
Mkt Cap28.24M	Tradable Cap10.31M	Total Shares6.37M
T/O101.67K	T/O Rate0.96%	Tradable Shares2.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XCUR","market":"US","secType":"STK","nameCN":"Exicure, Inc.","latestPrice":4.43,"timestamp":1773864000000,"preClose":4.54,"halted":0,"volume":22393,"hourTrading":{"tag":"盘后","latestPrice":4.66,"preClose":4.43,"latestTime":"18:24 EDT","volume":1242,"amount":5557.2599448,"timestamp":1773872668929,"change":0.23,"changeRate":0.051919,"amplitude":0.051919},"delay":0,"changeRate":-0.024229074889867912,"floatShares":2327862,"shares":6373869,"eps":-1.4479432,"marketStatus":"Post-Mkt","change":-0.11,"latestTime":"03-18 18:48:31 EDT","open":4.46,"high":4.66,"low":4.34,"amount":101668.43660189999,"amplitude":0.070485,"askPrice":4.88,"askSize":51,"bidPrice":4.36,"bidSize":47,"shortable":3,"etf":0,"ttmEps":-1.4479432,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773878400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":4.54,"preHourTrading":{"tag":"盘前","latestPrice":4.63,"preClose":4.54,"latestTime":"09:21 EDT","volume":3240,"amount":14910.746652,"timestamp":1773840107475,"change":0.09,"changeRate":0.019824,"amplitude":0.054075},"postHourTrading":{"tag":"盘后","latestPrice":4.66,"preClose":4.43,"latestTime":"18:24 EDT","volume":1242,"amount":5557.2599448,"timestamp":1773872668929,"change":0.23,"changeRate":0.051919,"amplitude":0.051919},"volumeRatio":0.747325},"requestUrl":"/m/hq/s/XCUR/wiki","defaultTab":"wiki","newsList":[{"id":"2612968774","title":"Exicure Inc - Appoints Gyuyeob Lee as Interim CFO - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612968774","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612968774?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:32","pubTimestamp":1771367548,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD1BG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2612879496","title":"Exicure Inc - Andy Yoo Resigns as CEO and President of Exicure - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612879496","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612879496?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:32","pubTimestamp":1771367548,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD1BG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2612495059","title":"Exicure Inc. Appoints Jung Soo Kim as CEO and Gyuyeob Lee as Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2612495059","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612495059?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:25","pubTimestamp":1771367154,"startTime":"0","endTime":"0","summary":"Exicure Inc. has appointed Jung Soo Kim as Chief Executive Officer and President, and Gyuyeob Lee as Interim Chief Financial Officer and Secretary, effective February 11, 2026. They replace Andy Yoo and Seung Ik Baik, who resigned from their respective positions effective February 9, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL8DPh1W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2610679196","title":"Exicure Inc. Appoints Three New Directors as CEO and CFO Resign","url":"https://stock-news.laohu8.com/highlight/detail?id=2610679196","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610679196?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:26","pubTimestamp":1770758786,"startTime":"0","endTime":"0","summary":"Exicure Inc. announced that Andy Yoo and Seung Ik Baik have resigned from their roles as Chief Executive Officer and Chief Financial Officer, respectively, effective February 9, 2026. Additionally, Andy Yoo, Seung Ik Baik, and Aejin Hwang have resigned from the Board of Directors. The board has appointed Jung Kyu Ham, Jung Soo Kim, and Gyeung Seog Cheon as new directors, with Mr. Cheon also joining the audit committee. The CEO and CFO positions will remain vacant until new appointments are made.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL3C98Bm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2609374199","title":"Exicure kündigt erfolgreiche Phase-2-Studie mit Burixafor zur schnellen Stammzellmobilisierung bei Multiplem Myelom und Lymphom an","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374199","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609374199?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:00","pubTimestamp":1770292826,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL7XbNjq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4588","BK4112","NDAQ","IE00B3QW5Z07.USD","BK4139","SG9999014005.SGD","SG9999014021.USD","BK4585","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","XCUR"],"gpt_icon":0},{"id":"2609374110","title":"Exicure Reports Phase 2 Success for Burixafor in Rapid Stem Cell Mobilization for Transplant Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374110","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609374110?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:00","pubTimestamp":1770292826,"startTime":"0","endTime":"0","summary":"Exicure Inc. has announced the publication of results from a Phase 2 clinical study evaluating burixafor, a highly selective CXCR4 inhibitor, in the journal Annals of Hematology. The study assessed burixafor in combination with granulocyte colony-stimulating factor  in patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin disease undergoing autologous stem cell transplantation. The results showed that 92% of participants met the primary endpoint of collecting at least 5.0 × 10 CD34+ cells/kg within two leukapheresis sessions, with half achieving the target in a single session. Burixafor demonstrated rapid stem cell mobilization, with peak CD34+ cell counts occurring within one hour of administration, and was generally well tolerated. Additionally, Exicure recently completed another Phase 2 study evaluating burixafor in combination with G-CSF and propranolol in multiple myeloma patients. Positive topline data from this study were presented at the American Society of Hemato","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL8W2r61:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","LU0314104364.USD","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","BK4139","XCUR","BK4112"],"gpt_icon":0},{"id":"2605417795","title":"Exicure Achieves Milestone in Collaboration with GPCR Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2605417795","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605417795?lang=en_us&edition=fundamental","pubTime":"2026-01-23 05:29","pubTimestamp":1769117392,"startTime":"0","endTime":"0","summary":"Exicure Inc. has achieved the first milestone under its License and Collaboration Agreement with GPCR Therapeutics Inc., following the completion of a Phase 2 clinical trial for its novel stem cell mobilizer. As part of the agreement, Exicure will make a $1 million milestone payment to GPCR Therapeutics Inc. This collaboration focuses on the development of Burixafor , a small molecule CXCR4 inhibitor, and the milestone completion also activates a future sublicensing income-sharing arrangement between the two companies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Se","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL2B9pdd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2605101748","title":"Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2605101748","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605101748?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:15","pubTimestamp":1768997740,"startTime":"0","endTime":"0","summary":"Exicure (XCUR) announced that it will present a poster at the upcoming 2026 Tandem Meetings Transplantation & Cellular Therapy Meetings of the Amer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exicure-to-present-data-from-burixafor-phase-2-trial-at-2026-tandem-meetings-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exicure-to-present-data-from-burixafor-phase-2-trial-at-2026-tandem-meetings-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2605562101","title":"Exicure Reports Positive Phase 2 Results for Burixafor in Multiple Myeloma Stem Cell Mobilization","url":"https://stock-news.laohu8.com/highlight/detail?id=2605562101","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605562101?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:00","pubTimestamp":1768996826,"startTime":"0","endTime":"0","summary":"Exicure Inc. announced that it will present data from its open-label, multicenter Phase 2 trial evaluating burixafor in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation at the 2026 Tandem Meetings, taking place February 4-7, 2026, in Salt Lake City, UT. The poster presentation will feature previously reported results, highlighting that 89.7% of patients met the primary endpoint for successful stem cell mobilization using a regimen of burixafor, propranolol, and G-CSF. The data indicate that the combination provided reliable mobilization and a favorable safety profile. The presentation is scheduled for February 5, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the origi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDLbNcWGJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014021.USD","BK4588","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","BK4585","SG9999014013.SGD","XCUR","NDAQ","BK4139","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014039.USD","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2605608145","title":"Exicure HiTron Inc. Reports Disposal of Exicure Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605608145","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605608145?lang=en_us&edition=fundamental","pubTime":"2026-01-21 03:09","pubTimestamp":1768936192,"startTime":"0","endTime":"0","summary":"Exicure HiTron Inc., a beneficial owner of Exicure Inc., has reported a disposal of common shares of Exicure Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL1H22lN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Exicure HiTron Inc. Reports Disposal of Exicure Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2602032317","title":"Exicure HiTron Inc. Reports Disposal of Exicure Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602032317","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602032317?lang=en_us&edition=fundamental","pubTime":"2026-01-09 09:43","pubTimestamp":1767922999,"startTime":"0","endTime":"0","summary":"Exicure HiTron Inc., a significant beneficial owner of Exicure Inc. , has reported the disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL8jK7f1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Exicure HiTron Inc. Reports Disposal of Exicure Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2590323126","title":"Crude Oil Down 1%; AutoZone Shares Dip After Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2590323126","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590323126?lang=en_us&edition=fundamental","pubTime":"2025-12-10 01:11","pubTimestamp":1765300316,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/12/49285954/crude-oil-down-1-autozone-shares-dip-after-q1-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALEX","BK4214","LU0861579265.USD","LU1221951046.USD","LU1934455194.USD","PHR","BK4167","LU1571399168.USD","BK4166","BK4139","LU1037948541.HKD","BK4585","LU0345770308.USD","BK4563","LU0965509010.AUD","LU0965509101.SGD","TROX","SLMDA","LU0965508806.USD","LU0314106906.USD","BK4588","LU1934455863.HKD","LU2517655291.USD","LU1032955483.USD","LU2517655374.HKD","LU0345770993.USD","XCUR","LU2517655028.SGD","LU0965509283.SGD","LU1934455277.USD","LU1196500208.SGD","AZO","BK4090","BK4212","LU1221951129.SGD","LU1037948897.HKD","LU1506573853.SGD","SLM","LU2463526074.USD","LU0234570918.USD","BK4160","LU0053666078.USD"],"gpt_icon":1},{"id":"2590323374","title":"Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590323374","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590323374?lang=en_us&edition=fundamental","pubTime":"2025-12-10 00:39","pubTimestamp":1765298340,"startTime":"0","endTime":"0","summary":"Exicure shares trade higher after Phase 2 data show nearly 90% of patients reached key cell collection targets using its burixafor combination in multiple myeloma.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/09/Molecule-Of-Dna-Forming-Inside-The-Test-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/09/Molecule-Of-Dna-Forming-Inside-The-Test-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49284762/exicure-rally-fueled-by-rapid-cell-boosting-results-in-blood-cancer-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49284762/exicure-rally-fueled-by-rapid-cell-boosting-results-in-blood-cancer-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["IE00BJJMRZ35.SGD","LU2129689605.HKD","IE00BKVL7J92.USD","LU0234572021.USD","LU1066051225.USD","LU1506573853.SGD","LU0203345920.USD","LU0345770308.USD","LU1057294990.SGD","LU2750360641.GBP","IE00BLSP4239.USD","IE0002270589.USD","LU1935042991.SGD","LU0432979614.USD","LU2129689514.USD","LU1430594728.SGD","LU2468319806.SGD","LU1196500208.SGD","JNJ","SG9999002224.SGD","BK4588","LU1059921491.USD","IE00B1BXHZ80.USD","IE0034235303.USD","XCUR","IE00B19Z3581.USD","LU0889566641.SGD","IE0009355771.USD","IE00BSNM7G36.USD","BK4007","IE00B4R5TH58.HKD","LU0098860793.USD","IE00B3T34201.USD","LU1244550494.USD","LU2089984988.USD","LU1267930813.SGD","BK4581","LU1674673691.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU1894683348.USD","LU1585245621.USD","SG9999001440.SGD","LU1280957306.USD","LU0345770993.USD","LU1894683264.USD","LU1061106388.HKD","IE00B2B36J28.USD","IE0002141913.USD","SG9999002232.USD"],"gpt_icon":0},{"id":"2590613364","title":"Stocks to Watch: Alexander & Baldwin, Exicure, Mama's Creations","url":"https://stock-news.laohu8.com/highlight/detail?id=2590613364","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590613364?lang=en_us&edition=fundamental","pubTime":"2025-12-09 07:37","pubTimestamp":1765237020,"startTime":"0","endTime":"0","summary":"Alexander & Baldwin is being taken private in a $1.54 billion deal. Shares jumped 37% to $20.70 in after-hours trading Monday.Exicure shared positive results from a Phase 2 trial of its blood cancer treatment. The stock climbed 83% to $9.85 after the bell.Mama's Creations recorded a 50% bump in revenue. Shares rose 18% to $13.16.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAMA","XCUR","BK4212","BK4160","ALEX","BK4139"],"gpt_icon":0},{"id":"2590136159","title":"Exicure Surges on Positive Data for Blood Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590136159","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590136159?lang=en_us&edition=fundamental","pubTime":"2025-12-09 06:43","pubTimestamp":1765233780,"startTime":"0","endTime":"0","summary":"Exicure stock surged after the biopharmaceutical company announced positive results from a Phase 2 trial of its blood cancer treatment.The stock more than doubled in after-hours trading Monday to $11.91, after closing at $5.33.The company said 90% of patients with multiple myeloma who were undergoing stem cell treatment and received doses of burixafor, in combination with certain other treatments, achieved the primary endpoint of the study.The treatment was effective even for participants who had previously received daratumumab, a therapy associated with reduced stem cell mobilization, Exicure said.The company added that the burixafor course of treatment demonstrated a good safety profile.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Exicure Surges on Positive Data for Blood Cancer Treatment","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2590036636","title":"Exicure Reports Positive Phase 2 Results for Burixafor in Multiple Myeloma Stem Cell Mobilization","url":"https://stock-news.laohu8.com/highlight/detail?id=2590036636","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590036636?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229422,"startTime":"0","endTime":"0","summary":"Exicure Inc. announced positive topline results from a completed Phase 2 clinical trial evaluating burixafor  in combination with propranolol and granulocyte colony-stimulating factor  for mobilizing hematopoietic progenitor cells  in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation. The data, presented at the 2025 American Society of Hematology  Annual Meeting, showed that approximately 90% of participants achieved the primary endpoint of collecting ≥2 × 10 CD34+ cells/kg within two leukapheresis sessions. The study reported a favorable safety profile and rapid mobilization kinetics, with peak peripheral CD34+ cell levels observed within one hour of burixafor administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL4MvDBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","IE00BKPKM429.USD","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4588","BK4585","SG9999014021.USD","SG9999014039.USD","BK4139","SG9999014005.SGD","LU2210150020.SGD","XCUR","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2584726546","title":"Exicure Inc. Announces Early Redemption of $3.1 Million Convertible Bonds to Simplify Capital Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2584726546","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584726546?lang=en_us&edition=fundamental","pubTime":"2025-11-18 05:53","pubTimestamp":1763416403,"startTime":"0","endTime":"0","summary":"Exicure Inc. has announced the early redemption of 4.5 billion KRW  in 2.90% Convertible Bonds originally due in 2028. The bonds, issued by its subsidiary KC Creation Co., Ltd. and held internally by Exicure, were redeemed in full on November 10, 2025. This move is part of Exicure's ongoing efforts to streamline its intercompany financing and secure liquidity for its biotechnology operations. The transaction, funded through internal cash transfers and involving no third-party holders, is not expected to have a material impact on the company's consolidated financial statements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gather","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL7lDcfG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2582388654","title":"Exicure Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2582388654","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582388654?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:18","pubTimestamp":1762809483,"startTime":"0","endTime":"0","summary":"Exicure Inc. held its 2025 Annual Meeting of Stockholders on November 6, 2025. During the meeting, stockholders elected two individuals to the board of directors and ratified the selection of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. All proposals presented at the meeting were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1vC6ZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2581831358","title":"Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2581831358","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581831358?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:11","pubTimestamp":1762549868,"startTime":"0","endTime":"0","summary":"Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operationsOverviewExicure reports Q3 net loss of $2.4 mln, up from $1.1 mln last yearCompany's cash p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL1N3WJ166:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2581397898","title":"Exicure Q3 EPS $(0.39) Up From $(0.57) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2581397898","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581397898?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:01","pubTimestamp":1762549318,"startTime":"0","endTime":"0","summary":"Exicure Q3 EPS $(0.39) Up From $(0.57) YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48734306/exicure-q3-eps-0-39-up-from-0-57-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Exicure Q3 EPS $(0.39) Up From $(0.57) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exicuretx.com","stockEarnings":[{"period":"1week","weight":0.1019},{"period":"1month","weight":0.1127},{"period":"3month","weight":-0.2186},{"period":"6month","weight":0.1701},{"period":"1year","weight":-0.6505},{"period":"ytd","weight":-0.1624}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0161},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0129},{"period":"1year","weight":0.1827},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Exicure, Inc. does not have significant operations. previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.050352},{"month":2,"riseRate":0.375,"avgChangeRate":-0.040535},{"month":3,"riseRate":0.375,"avgChangeRate":-0.022207},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.002351},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.024787},{"month":6,"riseRate":0.25,"avgChangeRate":-0.042251},{"month":7,"riseRate":0.25,"avgChangeRate":-0.052633},{"month":8,"riseRate":0.25,"avgChangeRate":-0.062697},{"month":9,"riseRate":0.25,"avgChangeRate":-0.030428},{"month":10,"riseRate":0.25,"avgChangeRate":-0.064735},{"month":11,"riseRate":0.5,"avgChangeRate":0.997962},{"month":12,"riseRate":0.5,"avgChangeRate":-0.072048}],"exchange":"NASDAQ","name":"Exicure, Inc.","nameEN":"Exicure, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Exicure, Inc.(XCUR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Exicure, Inc.,XCUR,Exicure, Inc.股票,Exicure, Inc.股票老虎,Exicure, Inc.股票老虎国际,Exicure, Inc.行情,Exicure, Inc.股票行情,Exicure, Inc.股价,Exicure, Inc.股市,Exicure, Inc.股票价格,Exicure, Inc.股票交易,Exicure, Inc.股票购买,Exicure, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Exicure, Inc.(XCUR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}